Jilin Cancer Hospital
Jilin Cancer Hospital in Changchun is the centre that led China's small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.
Overview
Provincial cancer centre whose thoracic oncology department under Cheng Ying has been principal investigator for serplulimab (ASTRUM-005), adebrelimab (CAPSTONE-1), benmelstobart plus anlotinib and other extensive-stage SCLC trials, making a north-eastern provincial hospital one of the most cited sites in the disease.
- Small cell lung cancer trials
- Thoracic oncology
Pages like this
not linked directly; found by shared links- CompanyShanghai Henlius Biotech
Shares ASTRUM-005, Serplulimab, Small-cell lung cancer and the tag china.
- ProductAnlotinib
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares Adebrelimab, CAPSTONE-1, Small-cell lung cancer and the tag china.
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Adebrelimab, Serplulimab, Small-cell lung cancer.
- TrialIMpower133
Shares CAPSTONE-1, Small-cell lung cancer.
- TrialCASPIAN
Shares CAPSTONE-1, Small-cell lung cancer.
- ProductPlatinum + etoposide (EP / CE)
Shares ASTRUM-005, Small-cell lung cancer.
- ProductEtoposide
Shares CAPSTONE-1, Small-cell lung cancer.